Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 14th 2015

Managed Care Minute: February 14, 2015

A one-minute look at managed care news during the week of February 9, 2015, including an announcement of a new Affordable Care Initiative and a potential change to recommended dietary guidelines.

February 13th 2015

Cancer Patients Rarely Request Inappropriate Tests, Treatments

Laura Joszt, MA

A new study debunks the common assumption that high medical costs are a result of patients demanding more tests and treatments. Researchers analyzed more than 5000 patient-clinician visits and found that cancer patients rarely push for medical interventions.

February 12th 2015

Order of Cancer Gene Mutations Could Influence Treatment Choice

The NEJM study, although specific for blood disorders, could be extrapolated to other tumor types as well, to develop personalized treatment regimens, the authors suggest.

February 12th 2015

HHS Announces New Oncology Care Management Initiative

Laura Joszt, MA

A new Affordable Care Act initiative from HHS will better coordinate cancer care with the intention of improving the quality of care provided and reducing the money spent on healthcare, according to an announcement from HHS.

February 12th 2015

Dr Debra Patt Discusses Community Oncology Practices

As community oncology clinics affiliate with hospital systems to become hospital outpatient departments, patients begin to feel the burden of higher costs of care, according to Debra Patt, MD, from Texas Oncology, a community-based practice.

February 12th 2015

Segment 11: High Cost Trends Trickling Into Other Disease Areas

Although the marketplace has managed to come to a temporary solution for the high cost of hepatitis C drugs, Steven Miller, MD, MBA, expects to see more examples of similar high-cost drugs in other categories.

February 12th 2015

New Approach Reduces Length of Stay, Costs in Colorectal Surgery

Laura Joszt, MA

A new approach to caring for patients undergoing colorectal surgery has shown faster recovery times, fewer complications, improved patient satisfaction, and reduced medical costs, according to a team of researchers.

February 11th 2015

Confirmed: Valeant to Buy Dendreon

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon.

February 11th 2015

Rare EGFR Mutations Need Additional Scrutiny in NSCLC, Study Warns

The results published in the Journal of Thoracic Oncology found that the response rate to tyrosine kinase inhibitor therapy was significantly higher in classic vs rare EGFR mutations.

February 10th 2015

Dr Bruce Feinberg Highlights Pathways as a Solution to High Costs in Oncology

The concept of pathways is the most widely adopted solution to reduce the high cost of cancer care, according to Bruce Feinberg, DO, vice president and chief medical officer of oncology at Cardinal Health Specialty Solutions.

February 10th 2015

Service Setting Impact on Costs for Bevacizumab-Treated Oncology Patients

Nicole M. Engel-Nitz, PhD Elaine B. Yu, PharmD, MS Laura K. Becker, MS Art Small, MD

For patients with lung or colorectal cancer, bevacizumab treatment patterns and healthcare costs varied by the setting of treatment initiation (physician office vs hospital outpatient).

February 10th 2015

Genetic Variation Could Prompt Hearing Loss in Young Cancer Patients on Cisplatin

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations associated with rapid hearing loss in young cancer patients treated with the drug cisplatin, as published in Nature Genetics.

February 10th 2015

Takeda's Ixazomib Improves PFS in Multiple Myeloma, Interim Analysis Finds

Interim analysis during a phase 3 study of Ixazomib in patients with relapsed or refractory multiple myeloma found that the drug improved the primary endpoint of progression-free survival.

February 9th 2015

Velcade Approved for Mantle Cell Lymphoma in Europe

The drug has been approved for treatment-naive patients who are ineligible for transplant.

February 6th 2015

FDA Approval for 3D Breast Imaging System Developed by an Academic Startup

The 3D breast imaging system, developed at the University of Rochester, is currently approved for diagnosing cancer in women who have signs or symptoms of the disease, or who have abnormal findings after a standard screening mammogram.

February 6th 2015

CMS Adds Medicare Coverage for LDCT Screening for Lung Cancer in Certain Patients

Mary K. Caffrey

Following an announcement that Medicare would cover preventive low dose computes tomography for lung cancer screening, CMS released a final national coverage determination today that includes details on eligibility criteria.

February 5th 2015

Study Results Support Early Treatment With Abiraterone in Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in the journal Lancet Oncology, conducted by the Institute of Cancer Research (ICR), London, provides evidence for the value of introducing abiraterone prior to chemotherapy in these patients.

February 5th 2015

Strategic Oncology Partnership Between AstraZeneca and MD Anderson

The industry-academic partnership is expected to boost clinical trials on investigational drugs and outcomes research, in gynecological cancers.

February 5th 2015

Pfizer to Buy Injectables Giant Hospira

With several of it's blockbusters going off-patent soon, Pfizer is looking at new avenues for expanding it's revenue.

February 5th 2015

FDA Commissioner Hamburg Stepping Down

After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.

February 4th 2015

Smoking Increases Risk of Mortality in CRC Survivors

A comprehensive study published in the Journal of Clinical Oncology found that colorectal cancer survivors who smoke cigarettes were at more than twice the risk of death than non-smoking survivors.

February 4th 2015

Evidence-Based Care Can Eliminate Gaps in Cancer Survival Rates

Laura Joszt, MA

Although African Americans have had lower colon cancer survival rates over the past 2 decades compared with white patients, researchers at the Stanford University School of Medicine have found evidence-based care can remove the racial disparity.

February 4th 2015

FDA Announces Measure to Ease Patient Access to Investigational Drugs

In his blog post on FDAVoice, Peter Lurie MD, MPH, associate FDA commissioner for public health strategy and analysis, announced the introduction of a draft form and a draft guideline that can be used by a physician to request access to an experimental drug or biological product that is still under development.

February 4th 2015

IOM Report Addresses Responsible Sharing of Clinical Trial Data

The report, according to ASCO, delineates responsibilities of different stakeholders towards ensuring responsible data sharing of trial results.

February 3rd 2015

Palbociclib Approved for Post-Menopausal Women With Advanced Breast Cancer

The efficacy of the CDK4/6 inhibitor was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease.

February 3rd 2015

Study Compares Adjuvant Radiotherapy With Observation in Low-Risk DCIS

The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.

February 3rd 2015

"Methylome" Could Distinguish Aggressive Triple-Negative Breast Cancer

The study identified distinct methylation patterns between the aggressive and benign forms of TNBC, which could provide an improved understanding of disease outcome.

February 3rd 2015

Cost-Effectiveness Decisions: Who Do You Trust?

A study published in the Journal of Thoracic Disease digs deep into understanding the assumptions in HEOR studies that evaluate the cost-effectiveness of personalized cancer treatments.

February 3rd 2015

Panel Discussion: The Road to Personalized Medicine: Clinical Utility and Reimbursement in Molecular Diagnostics

Panelists discuss ways to improve the focus on clinical utility in molecular diagnostics given challenges in the system and needs of patients.

February 2nd 2015

Study Substantiates Cost-Effectiveness of Biomarker-Based NSCLC Treatment

Multiplexed genetic screening for EGFR and ALK gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic NSCLC setting in the United States, researchers report in The Journal of Thoracic Oncology.

...

139 140 141 142 143 144 145 146 147

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions